Hydroxychloroquine might reduce mortality in patients with systemic sclerosis

Int J Rheum Dis. 2023 Aug;26(8):1640-1642. doi: 10.1111/1756-185X.14670. Epub 2023 Mar 18.

Authors

Eda Otman¹, Sercan Gucenmez¹, Dilek Solmaz¹, Servet Akar¹, Mustafa Ozmen¹

Affiliation

¹ Division of Rheumatology, Department of Internal Medicine, Ataturk Education and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey.

PMID: 36933946
DOI: 10.1111/1756-185X.14670

No abstract available

Keywords: hydroxychloroquine; mortality; predictors; scleroderma; systemic sclerosis.

Publication types

Letter

MeSH terms

Humans
Hydroxychloroquine / adverse effects
Patients
Scleroderma, Localized*
Scleroderma, Systemic* / diagnosis
Scleroderma, Systemic* / drug therapy

Substances

Hydroxychloroquine